A Single Ascending Dose of HRS-4029 in Healthy Subjects
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorBeijing Suncadia Pharmaceuticals Co., Ltd
About this trial
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
Eligibility criteria
Qualifiers
Age between 18 to 55 years.
Body mass index (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
Agreed to take effective contraceptive measures during and 3 months after the last dose of the study period.
Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written informed consent form (ICF).
Disqualifiers
Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded.
Vital signs, physical examination, 12-lead electrocardiogram,or laboratory examination deemed clinically significant by the investigator .
Subjects with positive tests for infectious diseases.
Female who are pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- HRS-4029
- Placebo
Treatment groups
55 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov